ReviewMarine drugs2025
Microbial Blue Bioprospecting: Exploring the Advances of Compounds Post-Discovery.
Review in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine biotechnology is an emerging field of research. There is scientific evidence of the strong potential of a multitude of marine microorganisms in biotechnology, with applications spanning the medical, pharmaceutical, cosmeceutical, nutraceutical and environmental recovery fields. However, despite the discovery of new natural compounds being of wide-ranging benefit, their practical application still remains difficult due to costs and lengthy validation processes. The strength of natural compounds is that, unlike synthetic or already-known compounds, they can have more specific functions and are generally environmentally friendly. This requires, however, that each newly discovered compound be assayed for its toxicity through tests on model cells and organisms. Research should therefore not stop with the simple discovery of new compounds but go beyond with the validation of their efficacy and safety, an issue that remains poorly addressed for products of marine bacterial origin. This review analyses current knowledge on natural compounds of marine bacterial origin, trying to focus on the necessary steps after their discovery, including the investigation of their non-toxicity to model organisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.